Author:
Bonnet Eric,Genoux Annelise,Bernard Jacques,Fauvel Josette,Massip Patrice,Perret Bertrand
Abstract
AbstractActive anti-HIV therapy can induce hypertriglyceridemia, low high-density lipoprotein (HDL) and insulin resistance, eventually accompanied by clinical lipodystrophy, associated loss of subcutaneous adipose tissue and an increase in abdominal adiposity. The frequency of these metabolic disorders is approximately 50% and host genetic factors might confer particular susceptibility. Variants of apolipoproteins (apo) A5 and C3, interacting withClin Chem Lab Med 2007;45:815–21.
Subject
Biochemistry, medical,Clinical Biochemistry,General Medicine
Reference28 articles.
1. Synergistic antiadi - pogenic effects of HIV type I protease inhibitors with tumor necrosis factor alpha : suppression of extracellular insulin action mediated by extracellular matrix - degrad - ing proteases;Mondal;AIDS Res Hum Retroviruses,2001
2. Bres - low JL An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and untranslated region polymorphisms;Dammerman;Proc Natl Acad Sci USA,1993
3. Nazih - San - derson Association of apolipoproteins and E with metabolic changes in HIV - infected adults treated with protease - inhibitor - containing antiretrovtral therapy;Bard;J Antiviral Ther,2006
4. HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissue , due to the accu - mulation of activated sterol regulatory element - binding proteins in the nucleus;Riddle;J Biol Chem,2001
5. Contribution of nucleosidic analogue reverse transcrip - tase inhibitors to subcutaneous fat wasting in patients with HIV infection;Mallal;AIDS,2000
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献